PT  - JOURNAL ARTICLE
AU  - von Guggenberg, Elisabeth
AU  - Uprimny, Christian
AU  - Klingler, Maximilian
AU  - Warwitz, Boris
AU  - Sviridenko, Anna
AU  - Bayerschmidt, Steffen
AU  - Di Santo, Gianpaolo
AU  - Virgolini, Irene J.
TI  - Preliminary clinical experience of cholecystokinin-2 receptor PET/CT imaging using the <sup>68</sup>Ga-labeled minigastrin analog DOTA-MGS5 in patients with medullary thyroid cancer
AID  - 10.2967/jnumed.122.264977
DP  - 2023 Jan 01
TA  - Journal of Nuclear Medicine
PG  - jnumed.122.264977
4099  - http://jnm.snmjournals.org/content/early/2023/01/19/jnumed.122.264977.short
4100  - http://jnm.snmjournals.org/content/early/2023/01/19/jnumed.122.264977.full
AB  - PET/CT imaging was performed in patients with advanced medullary thyroid cancer (MTC) with the new 68Ga-labeled minigastrin analog DOTA-DGlu-Ala-Tyr-Gly-Trp-(N-Me)Nle-Asp-1-Nal-NH2 (68Ga-DOTA-MGS5) to evaluate the cholecystokinin-2 receptor expression status. Methods: Six patients with advanced MTC underwent PET/CT imaging with 68Ga-DOTA-MGS5. From the images acquired one and two hours post injection (p.i.) preliminary data on the biodistribution and tumor targeting properties were evaluated in a retrospective analysis. Results: A total of 87 lesions with increased radiotracer uptake considered malignant (two local recurrence, eight lymph nodes, 27 liver and 50 bone lesions) was detected. In general, radiotracer accumulation in lesions was found higher two hours as compared to one hour p.i. (mean SUVmax/SUVmean of 7.2/4.4 versus 6.0/3.6). Conclusion: The preliminary results clearly demonstrate the potential of 68Ga-DOTA-MGS5 PET/CT in detecting local recurrence and metastases in patients with advanced MTC.